Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant

[1] Solari D(2019)Pituitary adenomas: what are the key features? what are the current treatments? where is the future taking us? World Neurosurg. 127 695-709

[2] Pivonello R(2019)Markers of metabolic syndrome in patients with pituitary adenoma: a case series of 303 patients Horm Metab Res. 51 709-13

[3] Caggiano C(2004)Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Español de Acromegalia, REA) Eur J Endocrinol. 151 439-46

[4] Guadagno E(2011)Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry Eur J Endocrinol. 164 877-84

[5] Chiaramonte C(2016)The Mexican acromegaly registry: clinical and biochemical characteristics at diagnosis and therapeutic outcomes J Clin Endocrinol Metab. 101 3997-4004

[6] Miccoli G(2017)Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database Endocr. Relat. Cancer 24 505-18

[7] Cavallo LM(2012)Predictors of morbidity and mortality in acromegaly: an Italian survey Eur J Endocrinol. 167 189-98

[8] Del Basso De Caro M(2019)Glucose metabolism in acromegaly: a meta-analysis of prospective interventional studies J Clin Endocrinol Metab. 104 2892-902

[9] Colao A(2013)Effects of medical therapies for acromegaly on glucose metabolism Eur J Endocrinol. 169 99-108

[10] Cappabianca P(2014)Pasireotide versus octreotide in acromegaly: a head-to-head superiority study J Clin Endocrinol Metab. 99 791-799

[1] Solari D(2019)Pituitary adenomas: what are the key features? what are the current treatments? where is the future taking us? World Neurosurg. 127 695-709

[2] Pivonello R(2019)Markers of metabolic syndrome in patients with pituitary adenoma: a case series of 303 patients Horm Metab Res. 51 709-13

[3] Caggiano C(2004)Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Español de Acromegalia, REA) Eur J Endocrinol. 151 439-46

[4] Guadagno E(2011)Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry Eur J Endocrinol. 164 877-84

[5] Chiaramonte C(2016)The Mexican acromegaly registry: clinical and biochemical characteristics at diagnosis and therapeutic outcomes J Clin Endocrinol Metab. 101 3997-4004

[6] Miccoli G(2017)Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database Endocr. Relat. Cancer 24 505-18

[7] Cavallo LM(2012)Predictors of morbidity and mortality in acromegaly: an Italian survey Eur J Endocrinol. 167 189-98

[8] Del Basso De Caro M(2019)Glucose metabolism in acromegaly: a meta-analysis of prospective interventional studies J Clin Endocrinol Metab. 104 2892-902

[9] Colao A(2013)Effects of medical therapies for acromegaly on glucose metabolism Eur J Endocrinol. 169 99-108

[10] Cappabianca P(2014)Pasireotide versus octreotide in acromegaly: a head-to-head superiority study J Clin Endocrinol Metab. 99 791-799